BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Syndax Pharmaceuticals Inc. Announces Appointment Of Richard P. Shea As Independent Director And Chair Of The Audit Committee


1/23/2014 6:47:29 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

WALTHAM, Mass., Jan. 23, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions.

Mr. Shea is currently senior vice president and chief financial officer of Momenta Pharmaceuticals, Inc. where he managed a Series C venture round and various public offerings, including Momenta's initial public offering, which have raised over $300 million. Mr. Shea has also served as chief operating officer and chief financial officer at Variagenics, Inc. where he closed and managed the merger with Hyseq Pharmaceuticals, Inc. and managed a mezzanine financing and the company's $80 million initial public offering.

"We are fortunate to have someone with Rick's financial and business experience joining our board at a critical time in Syndax's development," said Dennis Podlesak, chairman of Syndax's board of directors. "Rick's experience will be indispensable to Syndax as it prepares to begin the Phase 3 study of entinostat in women with ER+ metastatic breast cancer in the first half of this year."

Prior to Variagenics, Mr. Shea was vice president, finance at Genetics Institute, LLC where he oversaw the growth of the company's annual revenues from $88 million to more than $400 million while the company grew from 600 employees to over 1,600. Mr. Shea holds a bachelor's degree from Princeton University and an MBA from the Public Management Program at Boston University.

About Syndax Pharmaceuticals

Syndax is developing entinostat for the treatment of patients with therapy-resistant cancers. Entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism and has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in ER+ metastatic breast cancer. The company holds worldwide rights to entinostat, an oral, selective HDAC inhibitor that is expected to be evaluated in combination with exemestane in a pivotal Phase 3 clinical study for the treatment of ER+ metastatic breast cancer.

Corporate Contact:
Bob Goodenow
Chief Business Officer
Syndax Pharmaceuticals
(781) 419-1418
BGoodenow@Syndax.com

Media Contacts:
David Schull or Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com

SOURCE Syndax Pharmaceuticals, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES